Mortality · VITD-MORT-02 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
When researchers ran the most direct test of this claim, giving high-dose vitamin D to adults confirmed to be deficient and tracking who died, they found no survival advantage: in the large intensive-care trial [2] deaths were slightly higher in the vitamin D group. The same no-benefit result came back in deficient heart-failure patients [4] and in deficient COVID patients [16][12], and a very large trial in older adults showed no reduction in deaths either [8]. A few studies did point toward a benefit, but each has a serious weakness: one tiny trial also gave calcium so the effect cannot be pinned on vitamin D [15], and two others only looked positive until the numbers were properly adjusted [14][17]. A cohort study even found that deficient patients who were treated did not die less often than those who were not [19]. The panel therefore judged the claim unlikely to be true, while noting that no trial has yet tested long-term correction of deficiency in the general community with death as the main outcome.
The corpus contains several randomised trials that enrolled vitamin D-deficient adults, raised their 25(OH)D levels, and measured mortality, and these consistently show no benefit: the ICU trial [2] reported 90-day mortality of 23.5% with vitamin D versus 20.6% with placebo (P=0.26), and the heart-failure trial [4] reported 19.6% versus 17.9% (HR 1.09, P=0.726). Deficient-population COVID trials agree, with mortality 17.5% versus 18.8% (P=0.838) in [16] and a non-significant trend in [12]. The large unscreened trial [8] found an all-cause mortality HR of 1.04 (95% CI 0.93-1.18). The positive signals are fragile: [15] is N=53, open-label and co-administers calcium; [14] and [17] lose significance on adjustment ([14] multiple-model OR 0.61, 95% CI 0.35-1.05, P=0.075); and the treated-deficient subgroup in cohort [19] shows no benefit (adjusted OR 0.74, 95% CI 0.48-1.13, P=0.15). The contested point: The division is whether the consistent nulls, drawn from acute critical illness [2][14] and advanced heart failure [4], generalise to chronic community deficiency, where no trial in this corpus powers an all-cause mortality endpoint. A second contested point is directionality: oncology signals that look supportive are relapse-free or progression-free survival [5][18][7], not all-cause mortality, while D-Health [8] carries a numerically higher cancer-mortality hazard (exploratory HR 1.24, 95% CI 1.01-1.54, P=0.05).
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin D, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The single best test of the exact claim — confirmed-deficient adults, deficiency corrected, all-cause mortality as the primary endpoint [2] — is null with the point estimate favouring placebo, directly undercutting 'reduces mortality'.
The only nominally significant mortality benefit [15] is N=53, open-label, and co-administers calcium, so the survival effect cannot be attributed to vitamin D alone (confounding by co-intervention).
Where it remains uncertain. Every positive estimate is small, confounded by calcium co-administration [15], or non-significant after adjustment [14][17], and no corpus trial tests chronic community deficiency with a powered mortality endpoint.
Aleatory
Positive and null signals rest on few deaths in small trials ([15] N=53, [16] N=56, [17] N=101), so play of chance is large.
Epistemic
No corpus trial powers all-cause mortality in chronic community deficiency; the direct tests are in acute illness [2][14] and advanced HF [4].
Inferential
Oncology signals are relapse-free or progression-free survival [18][5][7], not all-cause mortality, so they are indirect for the claim.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Best-powered RCT in confirmed-deficient adults with mortality as primary endpoint: null, point estimate favours placebo.
Panel auditInternal validity: high · scope of inference: Critically ill ICU adults with confirmed baseline 25(OH)D <20 ng/mL at high risk for death.Key limitations: single acute bolus dose · critically ill population may differ from general deficient adults
RCT in low-25OHD heart failure with all-cause mortality primary endpoint: null.
“Mortality was not different in patients receiving vitamin D (19.6%; n = 39) or placebo (17.9%; n = 36) with a hazard ratio (HR) of 1.09 [95% confidence interval (CI): 0.69-1.71; P = 0.726].”
Panel auditInternal validity: high · scope of inference: Advanced heart failure patients with 25OHD <75 nmol/L.Key limitations: insufficiency threshold not deficiency · disease-specific population · signal of harm (more MCS implants)
Largest mortality RCT: null overall, with an exploratory cancer-mortality increase signal.
“The HR of vitamin D3 effect on all-cause mortality was 1.04 [95% CI 0·93 to 1·18]; p=0·47)”
Panel auditInternal validity: high · scope of inference: Unscreened older Australians aged 60+, predominantly vitamin D replete.Key limitations: population not deficient · bolus monthly dosing · does not test correction of deficiency
Median overall survival was identical (24.3 vs 24.3 months, P=.43).
Panel auditInternal validity: medium · scope of inference: Metastatic colorectal cancer patients on chemotherapy; comparison is dose level, not correction of deficiency.Key limitations: both arms supplemented (no untreated comparator) · small phase 2 · OS secondary endpoint
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct RCT evidence in deficient adults consistently fails to show a mortality benefit while the supportive signals are small, confounded, or post hoc, so the claim is likely false though not fully refuted given the absence of a powered mortality trial in chronic community deficiency.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Powered mortality RCT in chronic community deficiency. The exact population and endpoint of the claim are untested; every direct RCT here is in acute or advanced disease. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Double-blind placebo-controlled RCT enrolling community adults with confirmed 25(OH)D deficiency, sustained daily repletion, all-cause mortality as the pre-specified primary endpoint, powered for a modest hazard reduction.
Open question: Does sustained correction of vitamin D deficiency in chronically deficient community adults reduce all-cause mortality? Why it is still open: No corpus RCT enrols this population with mortality as a powered primary endpoint; direct tests are confined to acute illness [2][14] and advanced heart failure [4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19